Scott M. Hynes - Concepedia

Author

Scott M. Hynes

Eli Lilly (United States)

Also Known As

Hynes, S.M., S. Hynes, S.M. Hynes, Scott Hynes, Scott M. Hynes

Publications

780

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Hospital Universitario HM Sanchinarro The University of Texas MD Anderson Cancer Center HonorHealth Sarah Cannon

About

Scott M. Hynes is an author at Eli Lilly (United States) specializing in cancer therapeutics, radiation oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	363
2	Cancer Therapeutics	8	8	363
3	Pharmacology	7	7	339
4	Pathology	2	2	82
5	Health Sciences	1	1	24

Scott M. Hynes

Publications

734

Citations

H-Index

Page 1

	Year	Citations
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer David S. Hong, Jeffrey R. Infante, Filip Jankú, Journal of Clinical Oncology	2016	158
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients Berta Laquente, José A. López-Martín, Donald Richards, BMC Cancer	2017	72
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer Giorgio V. Scagliotti, Jin Hyoung Kang, David C. Smith, Investigational New Drugs Phase Ii EvaluationOncologyMedicineFirst-generation Chk1 InhibitorImmune Checkpoint Inhibitor	2016	68
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer Emiliano Calvo, Victor J. Chen, Mark S. Marshall, Investigational New Drugs Advanced CancerMedicinePharmacologyAnti-cancer AgentCancer Treatment	2014	57
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer Glen J. Weiss, Ross C. Donehower, Tara Iyengar, Investigational New Drugs Kinase InhibitorMedicinePharmacologyCheckpoint 1Immune Checkpoint Inhibitor	2012	56
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer Amita Patnaik, Michael S. Gordon, Frank Tsai, Cancer Chemotherapy and Pharmacology	2018	54
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer Thomas Wehler, Michael Thomas, Christian Schumann, Lung Cancer MedicinePharmacologyPathologyChk1 InhibitorBronchial Neoplasm	2017	50
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer Jeffrey R. Infante, Amita Patnaik, Claire F. Verschraegen, Cancer Chemotherapy and Pharmacology Advanced CancerOncologyMedicineEg5 InhibitorPharmacotherapy	2017	47
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors Emiliano Calvo, Fadi Braiteh, Daniel D. Von Hoff, Oncology	2016	40
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer Lauren A. Byers, Alejandro Navarro, Eric Schaefer, Clinical Lung Cancer	2021	36

Page 1